Mouse models of human disease can be generated by homologous recombination for germline loss-of-function mutations. However, embryonic-lethal phenotypes and systemic, indirect dysfunction can confound the use of knock-outs to elucidate adult pathophysiology. Site-specific recombination using Cre recombinase can circumvent these pitfalls, in principle, enabling temporal and spatial control of gene recombination. However, direct evidence is lacking for the feasibility of Cre-mediated recombination in postmitotic cells. Here, we exploited transgenic mouse technology plus adenoviral gene transfer to achieve Cre-mediated recombination in cardiac muscle. In vitro, Cre driven by cardiac-specific ␣ -myosin heavy chain ( ␣ MyHC) sequences elicited recombination selectively at loxP sites in purified cardiac myocytes, but not cardiac fibroblasts. 
Introduction
Gene targeting to generate loss-of-function mutations in the mouse has yielded remarkable advances in understanding the roles played by specific gene products in mammalian development and, to a lesser extent, human disease (1) . Inherent impediments, however, can complicate the use of conventional homologous recombination to elicit the role of genes in adult pathophysiology. For example, illustrated by the retinoblastoma protein (2), deletion of a protein which also serves essential functions in embryogenesis can result in early lethality, precluding the use of germline mutations to investigate the protein's function in any adult context. Other potential effects confounding conventional knock-outs include the risk of impaired fertility and generalized, systemic disorders, illustrated by knock-out mutations of transforming growth factor beta-1 (TGF ␤ 1): the ability to test specific hypotheses regarding the role of TGF ␤ 1 in adult disease is impeded by the animals' multifocal immunological disorders, poor viability, and absolute requirement for an immunodeficient background; coadministration of immunosuppressive drugs; or both (3, 4) . Related constraints are foreseeable for receptors or intracellular proteins that are required for TGF ␤ effects. Thus, given that germline mutations might not permit a definitive loss-of-function study in a specific adult context, methods to achieve gene inactivation in a regulatable or tissue-restricted manner are desired. Both yeast (5-7) and phage (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) site-specific recombinases have been used to achieve targeted recombination of mammalian genes. Thus, regulated expression of recombinase, in turn, can be used, in principle, to achieve tissue-restricted and/or stage-specific recombination to induce or inactivate predetermined genes.
Cre recombinase, from the P1 bacteriophage, has proven efficacious in mediating recombination in mammalian cells (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . The 38-kD Cre protein functions as a site-specific recombinase, splicing DNA between specific 34 bp sequences known as loxP sites. Each loxP site contains a dyad of 13 bp, separated by an 8-bp spacer that gives 5 Ј to 3 Ј orientation to the motif. Cre is capable of catalyzing three forms of recombination: excision, inversion, and integration, dictated by the orientation of loxP sites relative to each other. Excision or inversion occur when the loxP sites exist on the same strand of DNA (as direct versus inverted repeats, respectively); insertion can occur, using loxP sites on separate strands.
Cre-mediated recombination can be regulated by controlling the timing or spatial distribution of Cre expression via tissue-specific promoters (17) , ligand-inducible promoters (18) , and ligand-dependent Cre fusion proteins (16) . Kühn et al. (18) deleted a DNA polymerase ␤ gene, flanked by loxP sites (floxed), by expressing Cre in transgenic mice using an IFNdependent promoter, the Mx1 promoter. Densitometric analyses of Southern blots suggest that 100% of the pol ␤ alleles in liver and spleen were deleted after induction of Cre expression. Importantly, 65% of the allele was lost in cardiac tissue as well. This work provides preliminary evidence that Cre-mediated recombination can take place in adult myocardium, con-taining terminally differentiated muscle cells in which DNA synthesis ordinarily cannot occur, but relies on a Southern blot that does not establish whether recombination occurred in the postmitotic myocytes, versus the abundant populations of interstitial fibroblasts and other nonmuscle cells that largely comprise the adult heart; e.g., ‫ف‬ 85% nonmyocytes in murine heart (19) . The same limitation applies to a recent report demonstrating the utility of Flp recombinase in transgenic mice, where a 30% recombination frequency in DNA extracted from skeletal muscle leaves substantial room for doubt concerning the identity of cell types involved (7) . Despite the attractiveness of site-directed recombination for applications affecting terminally differentiated lineages such as cardiac or skeletal muscle, to date there has not yet been a definitive, direct test for the feasibility of site-directed recombination in an irreversibly postmitotic muscle cell.
Here, both a cardiac-specific promoter of Cre recombinase and an injection of recombinant adenoviruses (20) have been used to direct Cre expression in mouse myocardium: Cremediated recombination was found to occur both in cultured neonatal cardiac myocytes and the intact adult heart. These studies establish the utility of targeting Cre to myocardium, to achieve gene recombination even in postmitotic ventricular muscle cells.
Methods
Construction of the ␣ MyHC-Cre gene. The nuclear-localized Cre expression vector, pOG231 (provided by S. O'Gorman, Salk Institute, La Jolla, CA), was digested with SacI and HindIII, removing the cytomegalovirus (CMV) 1 promoter but retaining the ATG start site and SV40 nuclear localization signal (nls; CCCAAGAAGAAGAG-GAAGGTG ϭ PKKKRKV) in frame with the first codon of Cre cDNA (TTC ϭ S). The cardiac-specific murine ␣ -myosin-heavy chain (MyHC) promoter ( ␣ -5.5, provided by J. Robbins, University of Cincinnati, Cincinnati, OH) (21) was ligated as a SacI-HindIII fragment 180 bp upstream from the nls-Cre translational start site. The resulting ␣ MyHC-Cre expression vector comprises the ␤ MyHC 3 Ј untranslated region, ␣ MyHC promoter, ␣ MyHC noncoding exons 1 and 2 (with the corresponding introns), and exon 3 splice acceptor sequence, 180 bp upstream from the nls-Cre ATG start site.
Cell culture and transfection. Primary cultures of 2 d postnatal Sprague-Dawley rat cardiac myocytes and cardiac fibroblasts were prepared using enzymatic dissociation, Percoll purification, and serum-free medium containing DME/Hams medium F12 (1:1), 5 g и ml Ϫ 1 transferrin, 1 nM Na 2 SeO4, 1 nM LiCl, and 25 g и ml Ϫ 1 ascorbic acid (22) . Cells were plated at a density of 2 ϫ 10 5 cells per 7 mm well for adenoviral infection and 9 ϫ 10 5 cells per 35 mm well for DNA-mediated gene transfer. Transfection of neonatal cardiac myocytes and cardiac fibroblasts was carried out using lipofectamine, 1.0 g of the loxP-tagged CAG-CATZ reporter (23), 0.5 g of an SV40-driven luciferase reporter gene to correct for transfection efficiency, and 2.0 g of the test vector (pcDNA3, the CMV promoter alone; OG231, CMV-driven Cre recombinase; p1120, the ␣ MyHC promoter alone; or ␣ MyHC-driven Cre). Cells were incubated for 4.5 h at 37 Њ C in the lipofectamine/DNA solution, for 8 h in DME/Hams medium F12 (1:1) supplemented with 5% horse serum, and for 60 h in the serum-free medium, with the addition of 1 nM T3.
Transgenic mice. The ␣ MyHC-Cre gene was excised from the plasmid vector backbone using SacI and KpnI. A 6.9-kbp fragment of pCAG-CATZ (23), containing the ␤ -actin promoter, loxP-tagged chloramphenicol acetyltransferase (CAT) gene, and adjacent LacZ gene, was excised using SalI and PstI. DNA fragments were separated by electrophoresis through 1% agarose, and purified using Qiaex II reagents (QIAGEN Inc., Chatsworth, CA). The linear ␣ MyHC-Cre and CAG-CATZ genes were microinjected separately into the pronuclei of FVB/N zygotes (24), at a concentration of 2 ng/ l in 10 mM Tris-HCl (pH 7.4), 0.1 M EDTA, and injected embryos were transferred to pseudopregnant ICR females. Recombinant adenoviruses. Construction of Ad5/CMV/nls-LacZ, which directs the expression of Escherichia coli LacZ, fused to the nuclear localization signal of SV40 large T antigen, has been reported previously (25) . Ad5/CMV was created by subcloning the 1,276-bp BgIII-PvuII fragment containing the CMV immediate early promoter, polylinker, and bovine growth hormone polyadenylation site from pcDNA3 (Invitrogen Corp., San Diego, CA) between the unique BgIII and Klenow-blunted ClaI sites of the adenoviral shuttle vector p ⌬ E1sp1B (26) . The resulting plasmid (p ⌬ E1sp1B/CMV) was then cotransfected with pJM17 into permissive 293 host cells to generate Ad5/CMV by standard methods (27) . AdCre (containing the CMV-driven Cre recombinase) and AdMA19 (containing the firefly luciferase reporter gene separated from the CMV promoter by a loxP-flanked 1.3 kbp spacer) were generously provided by Dr. Frank Graham, McMaster University, Hamilton, Ontario (28) ; the spacer region of AdMA19 contains stop codons in all three reading frames. All adenoviruses were propagated in 293 cells, harvested, cesium chloride-purified, and titered as described (27) . Cardiac cells were infected with recombinant adenoviruses, after 24 h in serum-free medium, for 4 h at moi ranging from 0 to 300 plaque forming units (PFU) per cell, using 200 l of virus in DME per well. The viral solution then was aspirated from each culture and replaced with 1 ml of serum free media for 48 h.
In vivo gene transfer to mouse myocardium. Mice were anesthetized by intramuscular injection using 10 l/g of 4 mg/ml pentobarbital sodium in 20% ethanol, supplemented with 3 l/g as needed.
Mice were intubated using a PE-90 endotracheal tube and ventilated using a small animal Harvard respirator (rate, 90-100 per min; tidal volume, 3-5 ml). Connection of the respirator to the PE-90 tubing was formed with PE-160 tubing to ensure a loose fit and prevent barotrauma by lung overexpansion (29) . The skin overlying the sternum was incised, midline vessels of the sternum cauterized using bovie forceps, and the sternum divided. The sternum was retracted using 6-0 ligatures, and the heart was gently exteriorized using Crile forceps at the apex. Care was taken not to damage the lungs or great vessels in the process. The heart was briefly immobilized between the thumb and index finger of the operator and was injected at the apex over ‫ف‬ 2 s with 100 l of PBS (130 mM NaCl, 15 mM Na 2 HPO 4 , 15 mM NaH 2 PO 4 , 1 mM MgCl 2 , and 1 mM CaCl 2 ) containing the virus, using a Hamilton syringe equipped with a 31-gauge needle. The heart was then returned to the thoracic cavity and the sternum was closed. Over the next 15-30 min, upon return of spontaneous movement, the mice were removed from the ventilator and provided with 100% O 2 , with spontaneous respiration resuming within 15-30 s. Body temperature was maintained during these procedures using a heat lamp, and 100% O 2 was provided through a nose cone.
For initial validation studies, 12-wk-old ICR mice (35-40 g, Harlan Sprague Dawley, Inc., Indianapolis, IN) were inoculated with 10 10 PFU of Ad5/CMV/nls-LacZ ( n ϭ 5) versus Ad/CMV ( n ϭ 2) or the diluent ( n ϭ 2), and were killed at 7 d. For the AdCre plus AdMA19 coinjection studies, ICR mice were injected with 6 ϫ 10 7 PFU of AdCre ( n ϭ 2), 6 ϫ 10 7 PFU of AdMA19 ( n ϭ 3), both viruses each at 6 ϫ 10 7 PFU ( n ϭ 7), or 6 ϫ 10 7 PFU of Ad/CMV/nls-LacZ ( n ϭ 2). For Cre activation of CAG-CATZ in transgenic mice, 9.5-wk-old mice were injected with 2 ϫ 10 8 PFU of AdCre ( n ϭ 3) or of Ad/CMV ( n ϭ 2). Biochemical assays. Luciferase activity was monitored as the oxidation of luciferin in the presence of coenzyme A, using an Analytical Luminescence model 2010 luminometer (30). LacZ activity was de-1. Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; CMV, cytomegalovirus; MyHC, myosin-heavy chain; PFU, plaque-forming units; X-gal, 5-bromo-4-chloro-3-indolyl-␤ -D galactopyranoside.
termined using chlorophenol red-␤ -D -galactosidase as substrate (31) . Total protein was measured by the Bradford method (32). CAT activity was measured by the phase-extraction method (33) with 25 g of n -butyryl coenzyme A, 24 M D -threo-di-chloroacetyl-1,2 [ 14 C]chloramphenicol (DuPont-NEN, Boston, MA), and 100 l of lysate in 25 mM Tris-HCl, pH 7.4, using a Beckman LS6800 scintillation counter. For biochemical determinations of reporter gene activity in vivo, hearts were washed and homogenized for 15 s using a Tissumizer (Wheaton Science Products, Millville, NJ), in 250 l per 100 mg of 25 mM Tris phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM EDTA, 10% glycerol, and 1% Triton X-100, containing 1 mg/ml Pefabloc SC, 0.5 mg/ml EDTA, 10 g/ml leupeptin, 10 g/ml pepstatin, and 1 g/ml aprotinin as protease inhibitors. Homogenates were centrifuged at 10,000 g for 10 min at room temperature, and the supernatants were analyzed as described above for cultured cells.
Western blot analysis. For immunodetection of luciferase protein, cardiac myocytes were infected, as detailed above, with AdCre, AdMA19, or AdMA19 plus AdCre at an moi of 15 for each virus. Cell lysates (50 g of protein per lane) were resolved by electrophoresis through a 10% sodium dodecyl sulfate-polyacrylamide gel, in parallel with 300 ng of purified firefly luciferase (Boehringer Mannheim Biochemicals, Indianapolis, IN) as a positive control. Proteins were transferred electrophoretically to a 2-m nylon membrane (BioRad Laboratories, Richmond, CA), using 0.1 M cyclohexylaminopropane sulfonic acid: 10% methanol. The membrane was rinsed with buffer D (500 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.3% Tween 20) and incubated for 1 h at room temperature with a polyclonal rabbit antibody directed against luciferase (Cortex, San Leano, CA), using a 1:4,000 dilution in buffer D plus 0.2% fatty acid-free BSA. The membrane then was washed for 30 min at room temperature with 3 ϫ 50 ml of buffer D containing 3% Tween 20, incubated for 1 h at room temperature with secondary antibody (horseradish peroxidase-conjugated donkey antibody against rabbit IgG; Amersham Corp., Arlington Heights, IL), using a 1:10,000 dilution in buffer D plus 0.2% fatty acid-free BSA, and washed with 3 ϫ 50 ml of buffer D plus 3% Tween 20. Bound antibody was detected by chemiluminescence, using ECL reagents (Amersham Corp.).
PCR analysis. To demonstrate Cre-mediated recombination after transient transfection, using PCR, myocytes were harvested using 0.02% trypsin in PBS, and were incubated in 100 mM Tris-HCl, pH 7.5, 10 mM EDTA, 0.5% sodium dodecyl sulfate, 1 mg/ml proteinase K for 1 h at 56 Њ C. DNA was extracted in phenol/chloroform and was ethanol-precipitated. Oligonucleotides were synthesized corresponding to the 3 Ј end of the chicken ␤-actin promoter (5Ј-CTGCTAAC-CATGTTCATGCC-3Ј; AG2) and 5Ј end of the LacZ gene (5Ј-GGC-CTCTTCGCTATTACG-3Ј; Z3). PCR analysis was performed using Taq polymerase and 1 g of DNA from each myocyte transfection in a 50-l reaction mixture containing 500 mM KCl, 100 mM Tris-HCl, pH 9.0, 1.5 mM MgCl 2 , 1% Triton X-100, and 0.6 mM dNTPs. DNA was denatured at 94ЊC for 1 min; primers were annealed at 60ЊC for 1 min and extended at 72ЊC for 1 min for 32 cycles. Elongation time for the PCR reaction was selected to prevent amplification of the intact, 2,000-bp segment, while permitting amplification of the recombined, 690-bp segment (see Fig. 1 ).
Presence of the CAG-CATZ transgene was assessed by amplification of genomic DNA from tail samples, using a sense primer at the 5Ј end and antisense primer for the mid-portion of CAT cDNA, respectively (5Ј-CAGTCAGTTGCTCAATGTACC-3Ј; 5Ј-ACTGGT-GAAACTCACCGA-3Ј), and resulting in a 320-bp band. Primers were annealed at 60ЊC for 1 min and extended at 72ЊC for 1 min for 30 cycles. To identify ␣MyHC-Cre transgenic mice, a sense primer positioned at the 3Ј end of intron 2 of the ␣MyHC promoter (5Ј-ATGA-CAGACAGATCCCTCCTATCTCC-3Ј) was used with an antisense primer at the 5Ј end of the Cre coding region (5Ј-CTCATCAC-TCGTTGCATCATCGAC-3Ј), to amplify a 300-bp fragment. The primers were annealed at 59ЊC for 1 min, with extension at 72ЊC for 1 min, for 30 cycles of amplification. Conditions otherwise were those shown for PCR analysis of DNA from cultured cells.
For PCR analysis of Cre-mediated recombination in vivo, the primers, buffer, and conditions were identical to those used for recombination in the transiently transfected cells, except DNA samples were isolated from heart, liver, lung, skeletal muscle (quadriceps), or spleen at the time of necropsy. As a positive control, ␤-casein was amplified, using the following primers (sense, 5Ј-GATGTGCTC-CAGGCTAAAGTT-3Ј; antisense, 5Ј-AGAAACGGAATGTTGT-GGAGT-3Ј).
Histochemistry. For histological detection of reporter gene expression after injection of recombinant viruses, hearts were bisected, mounted in freezing medium, and frozen in liquid nitrogen, with exceptions where noted below. Sets of 4-6 m cryostat sections were obtained, spaced at 250 m intervals using a coronal plane of section, and were fixed in 4% formaldehyde for 10 min. At each interval, one section was used for hematoxylin-eosin staining and one for 5-bromo-4-chloro-3-indolyl-␤-D galactopyranoside (X-Gal) staining (34) , counterstained with nuclear fast red. The percentage of X-Gal-positive cells was estimated for each section, using cell number from the adjacent hematoxylin-eosin-stained section as the denominator.
For luciferase immunocytochemistry, tissue sections fixed as above were incubated with 0.3% H 2 O 2 in methanol to inactivate endogenous peroxidase activity, then were incubated with the antiluciferase antibody at a dilution of 1:75 in PBS plus 1% BSA. Sections were incubated overnight in a humidifying chamber at room temperature and washed three times. Bound primary antibody was visualized using biotinylated goat antibody against rabbit IgG, followed by avidin conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA). Sections were incubated in diaminobenzidine/ 10% hydrogen peroxide (Pierce, Rockford, IL) for 10 min and counterstained with eosin.
To detect Cre-dependent ␤-galactosidase expression by wholeorgan staining, tissues were harvested from 6-wk-old animals and fixed for 2 h at room temperature in 2% formaldehyde, 0.2% glutaraldehyde, 0.2% Nonidet P-40, 5 mM ethylenebis(oxyethylenenitrilo)tetraacetic acid, 2 mM MgCl 2 , 0.1 M sodium phosphate (pH 7.3). Samples were rinsed for 3 ϫ 30 min at room temperature in 0.1% deoxycholate, 0.2% Nonidet P-40, 2 mM MgCl 2 , 0.1 sodium phosphate (pH 7.3), stained for 3 h at room temperature with 1 mg/ml X-gal (Boehringer Mannheim Biochemicals), 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 , 0.1% deoxycholate, 0.2% Nonidet P-40, 2 mM MgCl 2 , 0.1 sodium phosphate (pH 7.3), and rinsed twice with PBS (35) .
Statistics. Statistical analysis was performed using ANOVA and Scheffe's multiple comparison test, using a significance level of P Ͻ 0.05.
Results
A cardiac-specific Cre vector mediates recombination selectively in cultured ventricular muscle cells. To achieve cardiac myocyte-restricted expression of Cre recombinase, Cre cDNA was placed under the transcriptional control of the cardiacspecific ␣MyHC promoter (21). In parallel experiments, cultured ventricular myocytes versus ventricular fibroblasts were cotransfected with the Cre-dependent reporter gene CAG-CATZ (23), together with the CMV promoter alone, CMVdriven Cre, ␣MyHC promoter alone, or ␣MyHC-driven Cre promoter (Fig. 1) . CAG-CATZ harbors a CAT gene flanked by loxP sites and driven by the chicken ␤-actin promoter (23); downstream of CAT is the E. coli ␤-galactosidase gene (LacZ; Fig. 1 A) . In the absence of Cre, the CAT gene prevents readthrough expression of LacZ. Conversely, when the CAT gene is excised by Cre-mediated recombination between the tandem loxP sites, LacZ becomes positioned adjacent to the ␤-actin promoter, permitting LacZ expression. The CMV promoter was able to direct Cre-mediated recombination effectively in both cell types. By contrast, ␣MyHC-Cre was active selec-tively, provoking gene recombination only in the ventricular myocytes (Fig. 1, C and D) . Adequate transfection of fibroblasts was verified both by the cotransfected luciferase control, and by the capacity of CAG-CATZ to function in this background, as verified by CAT activity of the unmodified CAG-CATZ reporter (Fig. 1 E) . Thus, Cre-mediated recombination can occur in neonatal ventricular myocytes.
To validate the above results, Cre-mediated recombination at the loxP sites was assessed using PCR (Fig. 1 B) . No recombination was detected when cardiac myocytes were cotransfected with CAG-CATZ and the control expression vector containing the CMV promoter alone. Thus, the appearance of LacZ protein and the predicted recombination event were each contingent on the delivery of Cre recombinase. Spontaneous recombination, while theoretically possible between the paired loxP sites, occurs under these conditions, if at all, at a frequency too low to be detected by PCR. The results shown in Fig. 1 B establish the Cre-dependence and appropriate size for the recombined gene in preparation for in vivo work, to be discussed below, and do not address the frequency for in vitro recombination, which is not germane to this report.
The ␣MyHC-Cre transgene directs cardiac-restricted recombination in CAG-CATZ mice. To establish the feasibility of cardiac-restricted recombination in vivo, the ␣MyHC-Cre construct was used to generate transgenic mice, and Cre-dependent reporter mice likewise were generated, using the chimeric CAG-CATZ gene described above. Transgene-positive mice were identified by PCR, using primers specific for each construct, respectively. 2 of 21 potential F 0 mice carried the CAG-CATZ gene; nine of 38 potential F 0 mice bore the ␣MyHC-Cre gene. The CAG-CATZ founders 2104 and 2112 and ␣MyHC-Cre founder 2182 were arbitrarily selected for further characterization here. To establish that the CAG-CATZ reporter was transcriptionally competent in adult myocardium, tissue extracts from F 1 progeny were analyzed for expression of the CAT gene. As anticipated, the loxP-flanked CAT gene was highly active in myocardium and other organs of CAG-CATZ ϩ mice, whereas the LacZ gene, distal to the second loxP site, was silent (data not shown).
To test for Cre-mediated recombination of the CAG-CATZ target gene, CAG-CATZ F 1 mice and ␣MyHC-Cre F 0 mice were mated. As shown by PCR analysis (Fig. 2) , the ␣MyHC-Cre and CAG-CATZ transgenes each were inherited by roughly half the progeny, and two of the eight littermates received both genes. Myocardial recombination of the CAG-CATZ gene, assayed using the primers shown in Fig. 1 A, occurred only in the ␣MyHC-Cre ϩ /CAG-CATZ ϩ double transgenic mice (Fig. 2 A, top) . Recombination was cardiac-restricted and contingent on the presence of both transgenes concomitantly (Fig. 2 B, bottom) . No background or spontaneous recombination was detected.
To demonstrate the functional consequences of Cre-depen- dent recombination, all eight littermates were analyzed by whole-organ X-gal staining of heart, liver, lung, skeletal muscle (quadriceps), and spleen (Fig. 3) . The induction of LacZ activity was specific to myocardium (blue) and was contingent on the ␣MyHC-Cre ϩ /CAG-CATZ ϩ genotype (Fig. 3 A, versus Fig. 3, B-D) . Because all organs tested in CAG-CATZ ϩ mice contain substantial CAT activity, the expression of LacZ selectively in myocardium cannot be ascribed to tissue-restricted transcription of the Cre-dependent reporter gene. Conversely, CAT activity in myocardium was reduced ‫ف‬ 90% in ␣MyHC-Cre ϩ /CAG-CATZ ϩ mice, relative to expression in mice harboring CAG-CATZ alone (data not shown). A localized region of X-Gal staining extrinsic to the lung in Fig. 3 A is consistent with the previously noted activity of the ␣MyHC promoter in pulmonary veins (21).
To substantiate that Cre-dependent recombination in fact had occurred in ventricular myocytes themselves, induction of LacZ protein in myocytes was corroborated by both histochemical staining (Fig. 4) and by immunolocalization (not shown). Roughly 90% of ventricular myocytes were LacZ-positive, for the specific strain and time point illustrated in Fig.  4 C. Other ␣MyHC-Cre strains resulted in differing degrees of LacZ activation (e.g., Fig. 4 D) , which were unrelated to copy number (data not shown), consistent with insertional and positional effects or, potentially, differential methylation.
Adenoviral gene transfer to adult mouse myocardium in vivo.
Because the ␣MyHC promoter becomes transcriptionally active shortly after birth, in part resulting from the postnatal rise in thyroid hormone expression (21, 36), the foregoing experiments do not attest to the feasibility of Cre-mediated recombination in postmitotic ventricular muscle, which could be desirable or mandatory in other contexts. In preparation for adenoviral delivery of Cre/lox reagents to adult myocardium in vivo, pilot studies first were performed with a recombinant virus encoding a nuclear-localized LacZ protein under the control of the CMV promoter (Ad5/CMV/nls-LacZ). Given the small size of the adult mouse heart, a heart rate of 450-600 contractions per minute, and the objective of maximizing the reproducibility for gene delivery, injections were performed under direct visualization, after a median sternotomy, exteriorization of the heart, and transient immobilization. Five mice were injected with Ad5/CMV/nls-LacZ, two with the empty vector carrying only the CMV promoter (Ad5/CMV), two with diluent, and all nine mice were killed 7 d after injection (Fig.  5) . To characterize the extent and reproducibility of gene delivery to adult mouse myocardium, four to five sections per heart were analyzed, ‫ف‬ 250 m apart. All hearts injected with Ad5/CMV/nls-LacZ were positive for LacZ, by X-gal staining, in three or more of these widely spaced sections (Fig. 5, C and  D) . No LacZ activity was detected, after injection of the diluent (Fig. 5, A and B) or Ad5/CMV (Fig. 5, E and F) . The percentage of LacZ-positive nuclei averaged 36Ϯ11% (n ϭ 5) in the region of injection and ranged between 22 and 55% (Fig. 5  G) . In these 7-d samples, a mononuclear infiltrate was present in the area of injection for hearts injected either with Ad5/ CMV/nls-LacZ or Ad5/CMV, consistent with evidence that viral antigens (in addition to virally delivered protein) evoke an immune response (37) .
Adenoviral delivery of Cre triggers recombination in cultured cardiac myocytes. As a second preparatory step-in vitro characterization of the adenoviruses bearing Cre and a Credependent reporter, for subsequent delivery to myocardium in vivo-neonatal rat ventricular myocytes were coinfected with viruses bearing the CMV-driven Cre recombinase (AdCre) and a CMV-driven, recombination-dependent luciferase gene (AdMA19; Fig. 6, A and B) (28) . The moi ranged from 3 to 300 for each virus. Luciferase activity was contingent on the presence of both AdCre and AdMA19, verifying effective suppression of the reporter by the loxP-flanked spacer region inserted between the CMV promoter and luciferase gene. Luciferase activity was maximal at 15 PFU per cell of AdCre and 150 PFU per cell of the reporter gene (193Ϯ41 ϫ 10 6 light units per g protein, 225-fold greater than the luciferase produced in the absence of Cre at this concentration of AdMA19). Lowlevel expression of luciferase by this vector in the absence of Cre is ascribed to spontaneous recombination between the two homologous loxP sites (28) . Luciferase activity decreased at higher total concentrations of virus than those illustrated, presumably because of cytopathic effects and/or promoter competition. Lysates of myocytes infected with AdCre, AdMA19, or both together, were used for Western blot analysis (Fig. 6 C) . Luciferase protein was detected as a 62-kD band, identical to the authentic protein standard, exclusively in cultures infected with AdCre and AdMA19 in tandem.
In vivo delivery of Cre triggers recombination in postmitotic ventricular muscle. To test for Cre-mediated recombination after adenoviral injection of adult mouse myocardium, mice were injected with AdCre alone (n ϭ 2), AdMA19 (n ϭ 3), or both in concert (n ϭ 5). Mice were killed 7 d after injection, and luciferase activity was assayed (Fig. 7 E) . Luciferase production was detected in all five hearts that received the Cre virus and Cre-dependent luciferase gene (P ϭ 0.0001 versus only AdCre; P ϭ 0.0004 versus only AdMA19); no significant production above the machine reagent blank was seen in any heart that received either virus alone.
To verify the site of Cre-mediated recombination, immunohistochemistry for luciferase protein in the injected hearts also was performed (Fig. 7, A-D) . Two mice coinjected with AdCre plus AdMA19, and two with Ad5/CMV/nls-LacZ, were killed at 3 d to minimize the complication of infiltrating cells in the area of injection. Hearts were sectioned as described previously and were stained for luciferase with the antibody used for the Western blot shown in Fig. 6 C. Localization of luciferase signal to terminally differentiated adult myocytes, among other cells, was confirmed in the area of injection for multiple adjacent sections.
Because Cre-mediated recombination of the coinjected reporter gene could, in theory, be contingent on the episomal state of the loxP-tagged viral genome, the CMV-driven Cre virus next was injected into apical myocardium of adult (9.5 wk) CAG-CATZ transgenic mice. Two mice were injected with the Cre virus and two with the empty CMV control; the hearts were harvested at 72 h for analysis by X-gal staining. Activation of the Cre-dependent lacZ gene was readily detected in Figure 3 . Whole-organ X-gal staining in littermates resulting from an ␣MyHC-Cre ϫ CAG-CATZ cross similar to that shown in Fig. 2 . Tissues from 6-wk-old animals were fixed and incubated for 3 h with 1 mg/ml X-gal. LacZ induction was evident in myocardium of double transgenic mice. Bar, 5 mm. the adult ventricular myocytes (Fig. 8) , establishing the feasibility for Cre-mediated recombination in this postmitotic cell background. Both mice that received the Cre virus expressed LacZ in the area injected, in eight or more sections spaced ‫ف‬ 250 m apart. The percentage of LacZ ϩ cells ranged from 60 to 80% at the site injected and, thus, was at least equal to that achieved with Ad/CMV/nls-LacZ. 10 ϫ40 fields, totaling at least 2,000 cells, were scored for each mouse. No lacZ staining was detected in control animals injected with the empty virus. Thus, the efficacy for acutely induced recombination in postmitotic ventricular myocytes after local delivery of Cre approaches the degree of recombination achieved (more widely throughout the myocardium) by sustained expression of the ␣MyHC-Cre gene.
Discussion
The capacity to trigger site-specific gene recombination, with both temporal and spatial control, has obvious attractiveness for cardiovascular research. Driven by ␣MyHC control sequences, the Cre transgene reported here catalyzes site-specific gene rearrangement selectively in cardiac myocytes. Moreover, the use of recombinant adenovirus as an acute delivery vehicle for Cre shows that recombination can be triggered by Cre even in postmitotic ventricular myocardium. Because a principal limitation of the available results was the absence of direct evidence that Cre-mediated recombination can be triggered in terminally differentiated, postmitotic cells, the importance of this investigation includes this proof of feasibility in vivo for this form of genetic switch in adult ventricular myocytes. Adenoviral delivery is especially well-suited for Cre-mediated recombination, given the capacity of recombinant adenoviruses for remarkably efficient gene transfer to ventricular myocytes (38, 39), skeletal muscle (40) , and other nonproliferating cells. More broadly, these findings suggest that a cardiac-restricted, drug-inducible Cre gene, as implemented for other proteins (41), could be used as an alternative means to trigger recombination selectively in adult heart. Offsetting these advantages, the ability to study functional consequences after viral delivery of Cre shares with other in vivo gene transfer studies a need for short-term end points that can be analyzed before the onset of inflammation, or, to accommodate long-term measurements, less immunogenic vectors (42) (43) (44) . The immunogenicity of Cre itself, a bacteriophage protein, may require alternative steps, such as induction of immune tolerance (45), immunodeficient recipients (46), or immunosuppression (43, (47) (48) (49) . Modifications by which the efficiency of the present system might be further improved include using paired loxP sites which differ from each other to further decrease the theoretical incidence of spontaneous recombination, and improve the ratio of Cre-dependent to Creindependent target gene expression using this binary switch. Even in the absence of such modification, the induction resulting from addition of exogenous recombinase compares favorably with the inducibility of other binary systems for regulated gene expression both in vitro and in vivo.
Additional work will be needed to map, in detail, the onset of recombination in this system, including possible effects of ␣MyHC transcription during cardiac organogenesis (50) . Mosaicism for LacZ expression could result from strain-specific or integration site-specific patterns of transcription affecting either or both transgenes. Mosaicism here is also likely to result, at least in part, from properties of the CAG-CATZ reporter, driven by a ␤-actin promoter the transcription of which is known to decrease in the adult heart (51). By contrast, because the chimeric Cre-dependent gene actively expresses CAT in the absence of Cre, the observed penetrance of LacZ activity in the double transgenic mice is unlikely to be affected by methylation from having maintained the CAG-CATZ reporter in an unexpressed state. Two issues favoring the use of histological tests to define Cre-mediated recombination in cardiac muscle are the exceedingly high proportion of nonmyocytes in adult murine heart (19) , which obviates simple reliance on PCR results, and possibly unequal expression of the Cre-dependent gene contingent on cell type, which would complicate extrapolations from myocardial homogenates. Potential advantages of the ␣MyHC-Cre transgene include the dependence of this promoter on thyroid hormone, suggesting one means to control the timing of recombination. Although this ␣MyHC promoter has the capacity to drive transgenes with exceptional uniformity (52), line-to-line differences in mosaicism were found to occur, as anticipated, which could prove useful in the analysis of dose-dependent defects. Whereas high degrees of uniformity would be especially desirable for mutations of secreted proteins, defined degrees of mosaicism could prove advantageous in contexts including, but not necessarily limited to, cell-autonomous defects, i.e., as foreseen for growth factor receptors, intracellular signaling proteins, structural proteins, enzymes, and transcription factors. As reported recently (53) , the use of single-copy transgenic mice with integration at a predetermined site provides a plausible means to override the heterogeneity inherent to conventional transgenic methods.
The experiments reported here concur with and extend a recent report, using viral delivery of Cre in vivo to activate a loxP-tagged transgene (54) . In the latter study, recombination in neurons was extrapolated from PCR evidence for recombination after intracerebral injection, taken together with the presence of LacZ in neurons after parallel injections of virus encoding LacZ directly: thus, the identity of cell types undergoing recombination was left unanswered, for both the brain and the heart. By contrast, we have demonstrated Cre-dependent activation of the CAG-CATZ transgene, after adenoviral delivery to adult ventricular muscle cells in vivo. Thus, our findings redress the concern that postmitotic cells might be refractory to recombination produced by Cre.
For cardiovascular research, one a priori appeal of the Cre/ lox system is its unique ability to selectively eliminate certain genes from myocardium (or, in principle, any component of the cardiovascular system for which a suitably specific promoter exists), while preserving the remainder of the body in a wild-type state. Beyond merely surmounting the vexing problem of embryonic or early postnatal lethality, such specificity also provides a much-needed means to ensure that the consequences of a given gene deletion are a result of the protein's function in the affected cells, and not an untoward, confounding systemic, or indirect effect. Moreover, viral delivery of Cre provides a versatile means to generate an array of organ-specific knock-out mutations, as a rapid, less costly alternative to constructing and maintaining an array of tissue-specific Cre mice, perhaps with greater spatial precision than existing promoters would provide. The ability shown here, to evoke gene recombination selectively in myocardium, even in terminally differentiated, postmitotic ventricular muscle cells, expands dramatically the biological context in which a genetic approach to causal relations becomes plausible in cardiovascular research. -D) or the empty CMV control (E-H), as shown, and was harvested 3 d after injection. Tissue was embedded in OCT solution (Triangle Biomedical Sciences), and frozen in isopentane over liquid N 2 ; cryostat sections were prepared using a thickness of 6 m. X-gal staining of cryostat sections was performed as described in Methods, except fixation was performed for 15 min at 0ЊC, and staining was carried out for 12 h at 37ЊC. Sections were counterstained with nuclear fast red. Representative low-and highpower fields are illustrated. Up to 80% of myocytes showed evidence of recombination in the region injected with Ad.CMV.Cre; no positive cells were detected in mice that received the control virus.
